What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Cancer
- Surgery
Her scientific interests lie mostly in Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Transplantation.
Her biological study spans a wide range of topics, including Immunology and Oncology.
As a part of the same scientific family, Suzanne R. Hayman mostly works in the field of Multiple myeloma, focusing on Dexamethasone and, on occasion, Corticosteroid and Combination therapy.
Her work deals with themes such as Hematology and Urology, which intersect with Surgery.
Her studies in Gastroenterology integrate themes in fields like Refractory, Neutropenia, Pathology, Hazard ratio and Survival analysis.
Her Transplantation study integrates concerns from other disciplines, such as Beta-2 microglobulin, Chemotherapy, Stem cell, POEMS syndrome and Organomegaly.
Her most cited work include:
- Improved survival in multiple myeloma and the impact of novel therapies (1718 citations)
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (768 citations)
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. (600 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Oncology.
Her study in Transplantation, Lenalidomide, Amyloidosis, Autologous stem-cell transplantation and AL amyloidosis falls within the category of Internal medicine.
Her work carried out in the field of Transplantation brings together such families of science as Survival analysis and Stem cell.
Her work is dedicated to discovering how Multiple myeloma, Dexamethasone are connected with Cyclophosphamide and other disciplines.
Her study in Gastroenterology is interdisciplinary in nature, drawing from both Progression-free survival, Hematology, Primary systemic amyloidosis, Very Good Partial Response and Hazard ratio.
The study incorporates disciplines such as Newly diagnosed and Clinical trial in addition to Oncology.
She most often published in these fields:
- Internal medicine (70.41%)
- Multiple myeloma (56.65%)
- Surgery (36.71%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (70.41%)
- Multiple myeloma (56.65%)
- Oncology (22.63%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Internal medicine, Multiple myeloma, Oncology, Amyloidosis and AL amyloidosis.
In her study, Progression-free survival is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine.
Her Multiple myeloma research is multidisciplinary, incorporating perspectives in Newly diagnosed, Survival analysis, Bone marrow and Hazard ratio.
Her Oncology study also includes
- Retrospective cohort study that connect with fields like Survival rate,
- Clinical trial that intertwine with fields like Venetoclax.
She has researched Amyloidosis in several fields, including Immunoglobulin light chain, Hematologic Response, Stage and Very Good Partial Response.
Her study with Transplantation involves better knowledge in Surgery.
Between 2017 and 2021, her most popular works were:
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. (67 citations)
- Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis (46 citations)
- Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. (35 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Suzanne R. Hayman spends much of her time researching Internal medicine, Multiple myeloma, Gastroenterology, AL amyloidosis and Amyloidosis.
Internal medicine is closely attributed to Oncology in her research.
Her Multiple myeloma study focuses on Lenalidomide in particular.
Her Gastroenterology study also includes fields such as
- Bone marrow together with Myeloma protein,
- Treatment response most often made with reference to Proteasome inhibitor.
Her research integrates issues of Survival rate, Interquartile range, Multivariate analysis and Proteinuria in her study of AL amyloidosis.
Her Amyloidosis study incorporates themes from Immunoglobulin light chain, Immunoglobulin Light-chain Amyloidosis, Hematologic Response and Very Good Partial Response.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
